ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

Interleukin-2

Also written as “Recombinant Human Interleukin-2 and Rituximab”, “IL-2 (interleukin 2)” and “Interleukin 2 subcutaneous injection”.

Its studies are mostly in Lymphoma, Non-Hodgkin · Carcinoma, Renal Cell · Carcinoma, Non-Small-Cell Lung · Melanoma · Neoplasms, led by 3 companies.

Drug pageInterleukin-2: every studyAll 216 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 4, since Sep 12, 20026 company-led studies, 2 open or runningNext primary completion: Aug 30, 2027 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Chironits history only30 open or runningphase 3since Sep 12, 2002Sep 12, 2002none ahead
Hangzhou Huasai Biomedicine22 open or runningphase 1since Jul 22, 2025Jul 22, 2025Aug 30, 2027phase 1 · NCT07105176
Clinigenits history only10 open or runningphase 4since May 10, 2013May 10, 2013none ahead

Also a collaborator on its studies: ORION Clinical Services.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Hangzhou Huasai Biomedicine only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Jul 22, 2025First study: phase 1 study in Advanced Non-Small Cell Lung CancerFirst studyNCT07105176 · 12 planned · China
  2. Sep 15, 2026Phase 1 study in Advanced NSCLCNCT07830342 · 24 planned · China

Ahead

  1. Aug 30, 2027Primary completion: phase 1 study in Advanced Non-Small Cell Lung CancerNCT07105176
  2. Oct 2028Primary completion: phase 1 study in Advanced NSCLCNCT07830342

TargetBeta

“Interleukin-2 receptor agonist”ChEMBL 37, by rule

Studies

All 2 Hangzhou Huasai Biomedicine leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07830342Advanced NSCLC · China1RecruitingOct 202824
NCT07105176Advanced Non-Small Cell Lung Cancer · China1RecruitingAug 30, 202712

How it is read

Names in the registry

  • “Interleukin-2”, 3 entries
  • “Recombinant Human Interleukin-2 and Rituximab”, 2 entries
  • “IL-2 (interleukin 2)”, 1 entry
  • “Interleukin 2 subcutaneous injection”, 1 entry
  • “High Dose Interleukin-2”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.